Similar articles

• Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.

  Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ. Wessels JA, et al. Arthritis Rheum. 2006 Apr;54(4):1087-95. doi: 10.1002/art.21726. Arthritis Rheum. 2006. PMID: 16572443
• Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.

  Dervieux T, Greenstein N, Kremer J. Dervieux T, et al. Arthritis Rheum. 2006 Oct;54(10):3095-103. doi: 10.1002/art.22129. Arthritis Rheum. 2006. PMID: 17009228
• Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.

  Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M. Drozdzik M, et al. Pharmacogenomics J. 2007 Dec;7(6):404-7. doi: 10.1038/sj.tpj.6500438. Epub 2007 Feb 27. Pharmacogenomics J. 2007. PMID: 17325736 Clinical Trial.
• The pharmacogenetics of methotrexate.

  Hider SL, Bruce IN, Thomson W. Hider SL, et al. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. doi: 10.1093/rheumatology/kem147. Epub 2007 Jun 24. Rheumatology (Oxford). 2007. PMID: 17586865 Review.
• C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.

  De Mattia E, Toffoli G. De Mattia E, et al. Eur J Cancer. 2009 May;45(8):1333-51. doi: 10.1016/j.ejca.2008.12.004. Epub 2009 Jan 12. Eur J Cancer. 2009. PMID: 19144510 Review.